Are Wegovy Prices Going Up in the UK?

The misconception: 'Wegovy prices are just pharmacies charging what they like'

A common assumption is that price variation across UK providers is arbitrary, clinics marking up a commodity product however they fancy. The reality is more structured than that. Wegovy is a branded prescription medicine manufactured by Novo Nordisk, and the ex-manufacturer price, plus the supply chain that sits between factory and patient, sets a genuine floor. Private providers then add the cost of the clinical infrastructure required by law: the prescriber's time, identity verification, record-keeping, pharmacovigilance, and dispensing. When a price looks dramatically lower than the market, something in that list is usually missing.

Eli Lilly's decision to raise Mounjaro's UK list price (the highest dose moving from around £122 to around £330 per four-week pen from September 2025, as widely reported) didn't directly set Wegovy's price, but it recalibrated what the market considers normal. Typical private Wegovy prices since then range roughly £149 to £375 per month depending on dose and provider. Those figures come with caveats: they are reported market observations, they shift, and they vary by dose. Treat them as context, not a quote.

You can read more about how UK Wegovy pricing is structured across the market if you want the fuller picture before you decide anything.

Whether Wegovy prices are still rising, and what the evidence suggests

Prices don't move in one direction indefinitely. The sharp rise seen in 2025 was partly driven by supply pressure as demand outpaced manufacturing capacity. As Novo Nordisk has expanded production and the market has matured, if you're trying to work out whether the Wegovy price is still going up, the picture is more nuanced than a simple yes or no. Whether that means costs come down meaningfully for UK patients depends on factors outside any single pharmacy's control: manufacturer pricing decisions, NHS commissioning volumes, and whether new competitors (including oral semaglutide) shift the landscape.

NICE's appraisal of semaglutide for weight management sets the framework for NHS access under NICE technology appraisal TA875, but NHS availability remains constrained by long waiting lists and strict eligibility. For people accessing treatment privately, the price question is live right now, not contingent on policy timelines. If you're weighing up whether to start or continue, our frequently asked questions cover what to expect at each stage.

One practical note: if you order by midday on a weekday and your consultation is approved, your treatment ships the same afternoon. That timing matters more than many people realise when stock windows shift.

What headline prices often leave out

A £X/month figure on its own tells you almost nothing. Across the market, that number may or may not include the prescriber consultation, the actual prescription fee, delivery charges, and any ongoing clinical support between orders. Some services charge separately for each; others bundle selectively. At the dose you actually end up on after titration (which takes several months) the total cost can look quite different from the starter-dose headline, and many patients researching whether the Wegovy price is going down find that the answer depends heavily on which dose and provider they are comparing.

It's also worth checking whether repeat orders involve any clinical re-review. Wegovy is a prescription-only medicine. Every new supply should involve a prescriber confirming that your progress, any side effects, and your current health picture still make continuing appropriate. That step costs time and therefore money. If a service doesn't mention it, ask. The NHS England guidance on weight-management injections is clear that these medicines should sit within a framework of clinical oversight, private providers are expected to follow the same principle.

Our clinical team's approach to this is described on the clinical oversight page if you'd like to understand how prescribing decisions are made at nume.

Why 'cheapest' is the wrong test for a prescription medicine

We'll say plainly what we tell every patient who asks: nume is not the cheapest option, and that's a deliberate choice. One transparent price covers everything listed above (consultation, prescription, delivery, aftercare) with no subscription and no auto-renewal. Every repeat is clinically re-reviewed. We lose the price comparison on purpose, because the comparison itself is misleading when services aren't offering the same thing.

For a prescription-only medicine with a growing counterfeit problem, the lowest price is often the highest risk. The MHRA has issued repeated warnings about fake weight-loss pens circulating online, including an enforcement operation in late 2025 that seized approximately 20 million doses of illegally traded medicines worth around £45 million. Pens sold without a clinical assessment, through unverified social media sellers or suspiciously cheap websites, have in some cases contained the wrong substance entirely. Reporting suspect sellers to the MHRA's Yellow Card service is one practical step anyone can take.

A small saving on a monthly pen is not the measure that protects your health. The questions that matter are: who reviewed your case, are they registered, is the medicine coming through the licensed UK supply chain, and is anyone checking in if something changes? Those are the costs worth paying, and if you are actively wondering whether the overall cost of Wegovy is going down, our pricing page sets out what is realistically driving those changes. If you want to explore whether treatment is right for you, starting a free consultation is the first step, a real prescriber reads your answers, the same day.